Table 1.
Entry demography of subjects included in this study.
| Demography | Patients with UC | Healthy controls |
|---|---|---|
| Number | 31 | 13 |
| Gender (male/female) | 13/18 | 4/9 |
| Age (years) | 36·9 ± 12·7 | 33·8 ± 5·32 |
| Duration of UC (years) | 7·58 ± 10·3 | |
| Clinical activity index (CAI) | 12·1 ± 2·97 | |
| Location of colitis† | Total colitis (16) | |
| Left-sided (15) | ||
| Concomitant medications† | 5-ASA (30) | |
| i.v. PSL (20) | ||
| Oral PSL (9) | ||
| Steroids free (2) | ||
| WBC (/µl) | 10821·3 ± 4237·9 | 5123·3 ± 1200·7 |
| CRP (mg/dl) | 1·8 ± 2·8 | 0·19 ± 0·13 |
| ESR (mm/h) | 32·8 ± 21·1 | 5·08 ± 3·04 |
| EI (score) | 11·0 ± 2·07 |
†
No patient had proctitis or received steroid enema. UC, ulcerative colitis; 5-ASA, 5-aminosalicylic acid (2·25 g/day); PSL, prednisolone (36·1 ± 24·1 mg/day, range 2·5–80 mg); i.v., intravenous administration; WBC, white blood cell count; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; EI, endoscopic index by Rachmilewitz (reference [19]).